Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today additional results from its Hamster Challenge Study: ...
Gainers: Five Prime Therapeutics (FPRX) +259%.Fuel Tech (FTEK) +96%.Equillium (EQ) +61%.Immuron (IMRN) +29%.Genfit (GNFT) +27%.Performance Shipping (PSHG) +25%.Revlon (REV) +21%.Eastside Distilling (EAST) +20%.Vaxart (VXRT) +20%.Myomo (MYO) +19%.Losers: eGain (EGAN) -29%.S...
Are These On Your Penny Stocks List Today? Penny stocks and small cap stocks, in general, are back on the radar on Wednesday. We’ve seen a relatively consistent rotation in the stock market this week. What’s more is that after this rotation and repositioning, it looks ...
Greenland Technologies Holding (GTEC) +88% on launching integrated electric drivetrain.Trxade Group (MEDS) +70%.Summit Wireless Technologies (WISA) +42% on Q4 guidance.Mogo (MOGO) +27% on Q3 results.Fulgent Genetics (FLGT) +16% on Q3 results.Affime...
Pfizer and BioNTech's announcement that, based on preliminary data, their COVID-19 vaccine is 90% effective and an emergency use authorization ((EUA)) is only weeks away has led to downward pressure on some of the second tier developers. If all goes according to plan, deployment could start b...
Developmental-stage COVID-19 vaccine stocks continued their recent downward trend last month. Over the course of October, for instance, Inovio Pharmaceuticals (NASDAQ: INO) lost 16.1% of its value; Novavax 's (NASDAQ: NVAX) stock fell by 23%; and Vaxart 's (NASDAQ: VXR...
Biogen BIIB -28% after FDA advisory committee snub of Alzheimer’s drug.Quidel (QDEL) -26%.HighPoint Resources HPR -25% on Q3 earnings release.Co-Diagnostics CODX -24%.Enlivex Therapeutics (ENLV) -21%.Liquidia Technologies LQDA -20% on Q3 earnings...
Vaxart (NASDAQ: VXRT) , the San Francisco-area clinical-stage biotech company, has made and lost millions for investors this year. On Feb. 3, at the beginning of the recession, Vaxart's shares opened at $1.32 a share, buoyed by a Jan. 31 announcement that it had started a progra...
It was a booming start for CureVac during its IPO in August with the stock popping by 250%. There have been some recent news concerning safety of the vaccine candidate. Market contenders are either ahead or behind the German biotech when considering the state of the clinical trial...
Inovio Pharmaceuticals (NASDAQ: INO) and Vaxart (NASDAQ: VXRT) are both small biotech companies that have made names for themselves by initiating coronavirus vaccine projects. So far, both have made some progress, and early clinical trials proceeded largely as planned. Their...
News, Short Squeeze, Breakout and More Instantly...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...